# Noom's GLP-1 Program Combines Medication With Behavioral Support for Weight Loss
Noom Med has launched a GLP-1 prescription program that pairs medication with the company's existing behavioral coaching platform. The approach addresses a gap in current weight loss treatment, where patients often receive prescriptions without ongoing behavioral support.
GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and increasing feelings of fullness. They represent a significant shift in weight loss pharmacology. However, medication alone shows mixed results when patients lack support for sustainable lifestyle changes.
Noom's model integrates its psychology-based app with medical oversight. Users receive personalized coaching alongside their prescriptions, addressing both the biological and behavioral aspects of weight management. The program includes access to healthcare providers who can adjust dosing and monitor side effects, while coaches help users navigate appetite changes and develop eating habits that support their medication's effects.
This dual approach reflects growing evidence that weight loss requires multiple intervention layers. Research in behavioral medicine shows that combining pharmacological treatment with structured coaching produces better long-term outcomes than either approach alone. Patients who receive behavioral support alongside GLP-1 medications show greater adherence and more sustained weight loss.
The program positions itself as "clinically-backed" and customized, suggesting medical oversight distinguishes it from direct-to-consumer GLP-1 services that may lack comprehensive support structures. This matters because GLP-1 medications carry side effects including nausea, vomiting, and potential for rapid weight regain if discontinued without behavioral foundations in place.
Noom's expansion into prescription medications represents a convergence of telehealth convenience with behavioral science. The company built its reputation on psychology-informed weight loss coaching before moving into the pharmaceutical space. This integration could appeal to users seeking more than just medication, though